Nuveen Asset Management, LLC Theravance Biopharma, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 495,727 shares of TBPH stock, worth $4.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

495,727

Previous 447,092 10.88%

Holding current value

$4.62 Million

Previous $3.6 Million 29.45%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 14, 2025	BUY	$7.93 - $10.08 $385,675 - $490,240	48,635 Added 10.88%	495,727 $4.66 Million
Q3 2024 Nov 14, 2024	BUY	$7.66 - $10.25 $799,527 - $1.07 Million	104,377 Added 30.46%	447,092 $3.6 Million
Q2 2024 Aug 09, 2024	BUY	$8.29 - $9.92 $1.52 Million - $1.81 Million	182,897 Added 114.44%	342,715 $2.91 Million
Q4 2023 Feb 14, 2024	SELL	$8.58 - $11.4 $40,926 - $54,378	-4,770 Reduced 2.9%	159,818 $1.8 Million
Q3 2023 Nov 14, 2023	BUY	$8.38 - $10.44 $60,830 - $75,783	7,259 Added 4.61%	164,588 $1.42 Million
Q2 2023 Aug 14, 2023	BUY	$10.16 - $11.92 $28,641 - $33,602	2,819 Added 1.82%	157,329 $1.63 Million
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $962,690 - $1.12 Million	-97,537 Reduced 38.7%	154,510 $1.68 Million
Q4 2022 Feb 14, 2023	BUY	$9.65 - $11.34 $732,184 - $860,411	75,874 Added 43.07%	252,047 $2.83 Million
Q3 2022 Nov 14, 2022	SELL	$8.39 - $10.22 $536,867 - $653,967	-63,989 Reduced 26.64%	176,173 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$8.41 - $10.34 $447,882 - $550,667	53,256 Added 28.49%	240,162 $2.18 Million
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $184,226 - $286,623	22,116 Added 13.42%	186,906 $1.81 Million
Q4 2021 Feb 14, 2022	SELL	$7.42 - $11.05 $88,498 - $131,793	-11,927 Reduced 6.75%	164,790 $1.65 Million
Q3 2021 Nov 12, 2021	SELL	$6.77 - $14.41 $74,165 - $157,861	-10,955 Reduced 5.84%	176,717 $1.26 Million
Q2 2021 Aug 16, 2021	SELL	$14.52 - $22.46 $61,201 - $94,668	-4,215 Reduced 2.2%	187,672 $2.73 Million
Q1 2021 May 17, 2021	BUY	$16.57 - $21.08 $28,616 - $36,405	1,727 Added 0.91%	191,887 $3.92 Million
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $289,952 - $392,575	-19,473 Reduced 9.29%	190,160 $3.38 Million
Q3 2020 Nov 16, 2020	SELL	$14.79 - $22.49 $89,035 - $135,389	-6,020 Reduced 2.79%	209,633 $3.1 Million
Q2 2020 Aug 14, 2020	SELL	$20.64 - $30.69 $1.79 Million - $2.65 Million	-86,492 Reduced 28.63%	215,653 $4.53 Million
Q1 2020 May 14, 2020	BUY	$17.84 - $31.21 $538,660 - $942,354	30,194 Added 11.1%	302,145 $6.98 Million
Q4 2019 Feb 14, 2020	SELL	$16.12 - $25.89 $94,140 - $151,197	-5,840 Reduced 2.1%	271,951 $7.04 Million
Q3 2019 Nov 14, 2019	BUY	$16.51 - $23.78 $936,100 - $1.35 Million	56,699 Added 25.64%	277,791 $5.41 Million
Q2 2019 Aug 15, 2019	BUY	$15.6 - $25.15 $3.45 Million - $5.56 Million	221,092 New	221,092 $3.61 Million

Others Institutions Holding TBPH

# of Institutions

129

Shares Held

46.5M

Call Options Held

600

Put Options Held

300

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $622M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Theravance Biopharma, Inc. Transaction History